Categories AlphaGraphs, Analysis, Health Care

Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect

Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results on Thursday, January 24.

Analysts expect the company to post earnings of 85 cents per share on a top-line of $5.98 billion during the fourth quarter. During the same period last year, the company had reported earnings of 68 cents per share on revenues of $5.4 billion.

The stock has mostly underperformed in the trailing 52 weeks, declining almost 9%, while the industry recorded a modest growth of 7%.

Bristol-Myers Squibb year over year product sales growth

Throughout last year, its flagship drug – Opdivo – struggled in the cut-throat competition in the oncology market. Despite strong demand, Opdivo, which accounts for about one-fourth of Bristol Myers’ total sales, faced stiff competition from rival Merck’s (MRK) Keytruda.

In the recent quarters though, thanks to a slew of regulatory approvals, Opdivo has been picking up in sales and the fourth quarter figures of the immuno-oncology drug will play a key role in deciding the trading direction.

During the prior- reported quarter, Opdivo outgrew its cardiovascular drug Eliquis in a rare instance. Eliquis is also meanwhile perceived as a growth driver for the company, delivering 35% sales growth in the first nine months. Market observers are expecting this growth trajectory to continue into the fourth quarter.

The top line is likely to get a boost from the label expansion of these products.

In a massive deal, Eli Lilly acquires Loxo Oncology

Also, keep a lookout for management comments on the recent purchase of Celgene during the earnings conference call. The transcript of the entire call will be available here.

On January 3, Bristol-Myers had said that it was acquiring Celgene in a $74-billion cash-and-stock transaction. Shares of Celgene jumped over 30% in the pre-market trading hours following the announcement, while Bristol-Myers Squibb shares plunged about 13%.

 

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text 

Most Popular

Netflix (NFLX): Four reasons why this leader will not be easy to overthrow

Netflix (NASDAQ: NFLX) has for long been the undisputed king of the streaming space. The streaming industry is seeing massive growth with several new players entering the field. It also

Fastenal (FAST) sees strong post-COVID prospects: Is the stock a buy?

The demand for services that involve minimal human interaction is on the rise as people continue to practice social distancing. Fastenal Co. (NASDAQ: FAST), a market-leading supplier of vending machines,

HEXO Corp. (HEXO) Earnings: 3Q21 Key Numbers

HEXO Corp. (NYSE: HEXO) reported its third-quarter 2021 earnings results today. Net revenue rose 2% year-over-year to CAD22.6 million. Net loss narrowed to CAD20.7 million from a loss of CAD19.5

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top